Filtered By:
Therapy: Immunotherapy
Nutrition: Vitamin A
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Intravitreal immunotherapy in noninfectious uveitis: an update
Expert Rev Clin Pharmacol. 2023 Sep 6. doi: 10.1080/17512433.2023.2256660. Online ahead of print.ABSTRACTINTRODUCTION: In the past several years, there have been numerous advances in pharmacotherapeutics for the management of uveitis and other ocular inflammatory diseases, including newer therapeutic agents and ocular drug delivery systems. One of the most attractive modes of drug delivery is the intravitreal route since it has proven to be safe and efficacious and prevents unwanted systemic adverse events related to the agent.AREAS COVERED: In this review, intravitreal delivery of various pharmacotherapeutic agents for no...
Source: Pharmacological Reviews - September 7, 2023 Category: Drugs & Pharmacology Authors: Nitin Kumar Menia Sashwanthi Mohan Aniruddha Agarwal Source Type: research
Biology and therapeutic targeting of vascular endothelial growth factor A
Nat Rev Mol Cell Biol. 2023 Jul 25. doi: 10.1038/s41580-023-00631-w. Online ahead of print.ABSTRACTThe formation of new blood vessels, called angiogenesis, is an essential pathophysiological process in which several families of regulators have been implicated. Among these, vascular endothelial growth factor A (VEGFA; also known as VEGF) and its two tyrosine kinase receptors, VEGFR1 and VEGFR2, represent a key signalling pathway mediating physiological angiogenesis and are also major therapeutic targets. VEGFA is a member of the gene family that includes VEGFB, VEGFC, VEGFD and placental growth factor (PLGF). Three decades ...
Source: Mol Biol Cell - July 26, 2023 Category: Molecular Biology Authors: Lorena P érez-Gutiérrez Napoleone Ferrara Source Type: research
Serous retinal detachment following non-small cell lung cancer immunotherapy
Can J Ophthalmol. 2023 Jan 24:S0008-4182(23)00006-6. doi: 10.1016/j.jcjo.2023.01.001. Online ahead of print.NO ABSTRACTPMID:36706793 | DOI:10.1016/j.jcjo.2023.01.001
Source: Canadian Journal of Ophthalmology - January 27, 2023 Category: Opthalmology Authors: Matthew Maguire Luke Herbert Source Type: research
Recent advances in improving intranasal allergen-specific immunotherapy; focus on delivery systems and adjuvants
Int Immunopharmacol. 2022 Oct 15;113(Pt A):109327. doi: 10.1016/j.intimp.2022.109327. Online ahead of print.ABSTRACTAllergen-specific Immunotherapy (AIT) is the main therapeutic strategy to control and treat allergic disorders. Intranasal Immunotherapy (INIT) was introduced as a needle-free, noninvasive, and efficient approach among various routes of allergen administration. Since direct exposure of nasal mucosa to allergen extracts could induce local and systemic reactions, recent studies focus on establishing novel formulations using various delivery systems and adjuvants to improve INIT efficacy. This review categorizes...
Source: International Immunopharmacology - October 18, 2022 Category: Allergy & Immunology Authors: Mahvash Sadeghi Ali Asadirad Khadijeh Koushki Sanaz Keshavarz Shahbaz Sajad Dehnavi Source Type: research
Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma
CONCLUSIONS: These findings indicate that the treatment of UM with a combination of oHSV-1 and poly(I:C) generates immune responses and enhances anti-tumoral activity, suggesting the need for further investigations and clinical trials of this combination.PMID:36030435 | DOI:10.1007/s00432-022-04272-y
Source: Herpes - August 28, 2022 Category: Infectious Diseases Authors: Sisi Liu Mingxin Li Fengqiao Sun Junwen Zhang Fusheng Liu Source Type: research
ATRA promotes PD-L1 expression to control gastric cancer immune surveillance
In conclusion, our study illustrated that ATRA attenuated the effect of PD-L1 blockade through upregulating PD-L1 and blocking PD-L1 expression is an important role for the generation of effective anti-tumor immune response in the combination of immunotherapy and chemotherapy or targeted therapy.PMID:35151642 | DOI:10.1016/j.ejphar.2022.174822
Source: European Journal of Pharmacology - February 13, 2022 Category: Drugs & Pharmacology Authors: Zhi-Lu Ma Yan-Li Ding Jing Jing Lin-Na Du Xu-Yang Zhang Hong-Min Liu Peng-Xing He Source Type: research
Peptide-based immunotherapy against oxidized elastin ameliorates pathology in mouse model of smoke-induced ocular injury
CONCLUSIONS: These data further support ox-elastin role in ocular damage in in part via elastin-specific antibodies, and support the corollary that PIT with ox-elastin attenuates ocular pathology. Overall, damage is associated with complement activation, antibody-dependent cell-mediated cytotoxicity, and altered cytokine signature.PMID:34487725 | DOI:10.1016/j.exer.2021.108755
Source: Experimental Eye Research - September 6, 2021 Category: Opthalmology Authors: B ärbel Rohrer Nathaniel Parsons Balasubramaniam Annamalai Crystal Nicholson Elisabeth Obert Bryan Jones Andrew D Dick Source Type: research
